IP Library › Assignment 050174/0428
Patent Assignment
Reel/Frame 050174/0428

Security Interest

Recorded: 2019-08-26 Pages: 20
Assignor
ENTERIS BIOPHARMA, INC.
Executed: 2019-08-26
Assignee
CADENCE BANK, N.A.
3399 PEACHTREE ROAD, N.E., SUITE 1900, ATLANTA, GEORGIA, 30326
Covered Properties (50)
Improved Oral Delivery of Peptides
Improved Bacterial Host Cell for the Direct Expression of Peptides
Enzymatic Reactions in the Presence of Keto Acids
Cell Lines for Expressing Enzyme Useful in the Preparation of Amidated Products
Fast-Acting Oral Peptide Pharmaceutical Products
Peptide Pharmaceutical for Oral Delivery
Pharmaceuticals for Oral Delivery
Solid Oral Dosage Forms
Room Temperature Stable Oral Calcitonin Formulation
Oral Delivery of Peptides Using Enzyme-Cleavable Membrane Translocators
Patent: 6,673,574 →
Application: 09/997,465 →
Publication: US 2003/0118610
Oral Peptide Pharmaceutical Dosage Form and Method of Production
Patent: 7,316,819 →
Application: 10/094,306 →
Publication: US 2003/0017203
Oral Delivery of Peptides
Patent: 8,088,734 →
Application: 10/761,481 →
Publication: US 2004/0197323
Nasal Calcitonin Formulation
Patent: 40,812 →
Application: 10/774,358 →
Bacterial Host Cell for the Direct Expression of Peptides
Patent: 8,227,241 →
Application: 11/076,260 →
Publication: US 2005/0221442
Enzymatic Reactions in the Presence of Keto Acids
Patent: 7,445,911 →
Application: 11/285,136 →
Publication: US 2006/0127995
Cell lines for expressing enzyme useful in the preparation of amidated products
Patent: 8,815,583 →
Application: 11/474,159 →
Publication: US 2006/0292672
Fast-Acting Oral Peptide Pharmaceutical Products
Patent: 8,093,207 →
Application: 11/567,454 →
Publication: US 2007/0134279
Bacterial Host Cell for the Direct Expression of Peptides
Patent: 8,216,822 →
Application: 11/928,936 →
Publication: US 2008/0057566
Bacterial Host Cell for the Direct Expression of Peptides
Patent: 8,252,580 →
Application: 11/928,994 →
Publication: US 2008/0102491
Bacterial Host Cell for the Direct Expression of Peptides
Patent: 7,553,655 →
Application: 11/929,079 →
Publication: US 2008/0102510
Peptide Pharmaceutical for Oral Delivery
Patent: 8,377,863 →
Application: 12/128,210 →
Publication: US 2009/0317462
Enzymatic Reactions in the Presence of Keto Acids
Patent: 8,163,871 →
Application: 12/284,552 →
Publication: US 2009/0023892
Nasal Calcitonin Formulations
Patent: 43,580 →
Application: 12/459,385 →
Oral Delivery of Peptide Pharmaceutical Compositions
Patent: 8,835,377 →
Application: 13/219,132 →
Publication: US 2012/0328666
Peptide Pharmaceutical for Oral Delivery
Patent: 8,513,183 →
Application: 13/283,055 →
Publication: US 2012/0040000
Peptide Pharmaceutical for Oral Delivery
Patent: 8,664,178 →
Application: 13/487,784 →
Publication: US 2012/0315325
Peptide Pharmaceutical for Oral Delivery
Patent: 8,592,366 →
Application: 13/487,856 →
Publication: US 2013/0034600
Bacterial Host Cell for the Direct Expression of Peptides
Patent: 8,835,161 →
Application: 13/544,228 →
Publication: US 2013/0034897
Peptide Pharmaceutical for Oral Delivery
Patent: 9,399,017 →
Application: 14/158,029 →
Publication: US 2014/0335169
Pharmaceuticals for Oral Delivery
Patent: 9,457,086 →
Application: 14/197,405 →
Publication: US 2014/0255479
Oral Delivery of Peptide Pharmaceutical Compositions
Patent: 9,504,727 →
Application: 14/484,745 →
Publication: US 2015/0125522
Solid Oral Dosage Forms
Patent: 9,833,411 →
Application: 14/993,294 →
Publication: US 2016/0199303
Pharmaceuticals for Oral Delivery
Patent: 9,526,785 →
Application: 15/184,971 →
Publication: US 2016/0296624
Pharmaceuticals for Oral Delivery
Patent: 9,744,140 →
Application: 15/353,213 →
Publication: US 2017/0056328
Solid Oral Dosage Forms
Application: 15/802,754 →
Publication: US 2018/0049987
Room Temperature Stable Oral Calcitonin Formulation
Application: 16/267,902 →
Publication: US 2019/0192442
Nasal calcitonin formulations
Application: 60/180,241 →
Oral delivery of peptides using enzyme-cleavable membrane translocators
Application: 60/250,055 →
Oral peptide pharmaceutical dosage form and method of production
Application: 60/274,317 →
Oral delivery of peptides
Application: 60/441,856 →
Bacterial host cell for the direct expression of peptides
Application: 60/552,824 →
Oral delivery of peptide pharmaceutical compositions
Application: 60/580,872 →
Enzymatic reactions in the presence of keto acids
Application: 60/630,748 →
Cell lines for expressing enzyme useful in the preparation of amidated products
Application: 60/693,612 →
Fast-acting oral peptide pharmaceutical products
Application: 60/748,954 →
Peptide Pharmaceutical for Oral Delivery
Application: 60/940,598 →
Pharmaceuticals for Oral Delivery
Application: 61/772,927 →
Pharmaceuticals for Oral Delivery
Application: 61/925,443 →
Solid Oral Dosage Forms
Application: 62/102,263 →
Room Temperature Stable Oral Calcitonin Formulation
Application: 62/371,377 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 23, 2006
From: MILLER, DUNCAN A.; MEHTA, NOZER M.; CONSALVO, ANGELO P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 018195/0030 →
Assignment of Assignor's Interest Dec 21, 2006
From: STERN, WILLIAM
To: UNIGENE LABORATORIES, INC.
Reel/Frame 018667/0900 →
Release of Security Interest Jul 13, 2007
From: LEVY, JAY
To: UNIGENE LABORATORIES, INC.
Reel/Frame 019550/0483 →
Amended and Restated Patent Security Agreement Oct 11, 2007
From: UNIGENE LABORATORIES, INC.
To: JAYNJEAN LEVY FAMILY LIMITED PARTNERSHIP
Reel/Frame 019943/0714 →
Security Agreement Oct 3, 2008
From: UNIGENE LABORATORIES, INC.
To: VICTORY PARK MANAGEMENT, LLC
Reel/Frame 021630/0352 →
Security Agreement May 22, 2009
From: UNIGENE LABORATORIES, INC.
To: VICTORY PARK MANAGEMENT, LLC
Reel/Frame 022728/0506 →
Assignment of Assignor's Interest Jun 17, 2009
From: STERN, WILLIAM; CONSALVO, ANGELO P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 022836/0458 →
Corrective Assignment to Correct the Error in Notarization. First Inventor's Name William Stern Incorrectly Typed as Nozer M. Mehta. Corrected to Be William Stern. Previously Recorded on Reel 022836 Frame 0458. Assignor(S) Hereby Confirms the Assignment. Jul 24, 2009
From: STERN, WILLIAM; CONSALVO, ANGELO P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 023005/0284 →
Assignment of Assignor's Interest Sep 7, 2012
From: MEHTA, NOZER M.; STERN, WILLIAM; GILLIGAN, JAMES P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 028913/0511 →
Assignment of Assignor's Interest Sep 12, 2012
From: STERN, WILLIAM
To: UNIGENE LABORATORIES INC.
Reel/Frame 028947/0938 →
Security Agreement Oct 4, 2012
From: UNIGENE LABORATORIES, INC.
To: VICTORY PARK MANAGEMENT, LLC, AS COLLATERAL AGENT
Reel/Frame 029074/0689 →
Assignment of Assignor's Interest Apr 26, 2013
From: UNIGENE LABORATORIES, INC.
To: ENTERIS BIOPHARMA, INC.
Reel/Frame 030300/0538 →
Assignment of Assignor's Interest Jul 23, 2013
From: UNIGENE LABORATORIES, INC.
To: UGP THERAPEUTICS, INC.
Reel/Frame 030856/0340 →
Assignment of Assignor's Interest Mar 13, 2014
From: MEHTA, NOZER M.; CONSALVO, ANGELO P.; RAY, MARTHA V.L.; MEENAN, CHRISTOPHER P.
To: UNIGENE LABORATORIES, INC.
Reel/Frame 032434/0567 →
Assignment of Assignor's Interest Mar 13, 2014
From: CONSALVO, ANGELO P.; MEHTA, NOZER M.; STERN, WILLIAM; GILLIGAN, JAMES P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 032434/0564 →
Assignment of Assignor's Interest Jul 19, 2016
From: UGP THERAPEUTICS, INC.
To: ENTERIS BIOPHARMA, INC.
Reel/Frame 039184/0797 →
Corrective Assignment to Correct the Nature of Conveyance Previously Recorded on Reel 039184 Frame 0797. Assignor(S) Hereby Confirms the Nunc Pro Tunc Assignment Effective 02/01/2016. Aug 15, 2016
From: UGP THERAPEUTICS, INC.
To: ENTERIS BIOPHARMA, INC.
Reel/Frame 039682/0212 →
Assignment of Assignor's Interest Nov 26, 2018
From: GILLIGAN, JAMES P.; MAURER, GEORGE R.; RAILKAR, ANIRUDDHA M.; BAUER, PHIL
To: TARSA THERAPEUTICS, INC
Reel/Frame 047580/0823 →
Assignment of Assignor's Interest Nov 26, 2018
From: TARSA THERAPEUTICS, INC.
To: TAURUS DEVELOPMENT COMPANY LLC
Reel/Frame 047580/0882 →
Assignment of Assignor's Interest Nov 26, 2018
From: DAGGS, THOMAS A.; SHIELDS, PAUL A.
To: ENTERIS BIOPHARMA, INC.
Reel/Frame 047580/0869 →
Assignment of Assignor's Interest Dec 11, 2018
From: MEHTA, NOZER M.; CONSALVO, ANGELO P.; RAY, MARTHA V.L.; MEENAN, CHRISTOPHER P.
To: UNIGENE LABORATORIES INC.
Reel/Frame 047739/0437 →
Release of Security Interest Aug 8, 2019
From: VICTORY PARK MANAGEMENT, LLC
To: UNIGENE LABORATORIES, INC.
Reel/Frame 050000/0762 →
Release of Security Interest Aug 8, 2019
From: VICTORY PARK MANAGEMENT, LLC
To: UNIGENE LABORATORIES, INC.
Reel/Frame 050000/0799 →
Release of Security Interest Aug 8, 2019
From: VICTORY PARK MANAGEMENT, LLC
To: UNIGENE LABORATORIES, INC.
Reel/Frame 050000/0796 →
Release of Security Interest Jun 28, 2023
From: CADENCE BANK, A MISSISSIPPI BANK AND SUCCESSOR BY MERGER TO CADENCE BANK, N.A., A NATIONAL BANKING ASSOCIATION, AS AGENT
To: ENTERIS BIOPHARMA, INC.
Reel/Frame 064149/0741 →